Treatment of Chronic Lymphocytic Leukemia in the Elderly

Hamed, Nahla A M

doi:10.19080/ctoij.2017.03.555620

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many reports showing that advanced age reduces the survival and is a poor prognostic factor in CLL. Fragility and poor treatment tolerance in advanced age also contributes to worsening prognosis [20][21][22]. Presence of anemia or thrombocytopenia which is Unlike similar studies, in our study progression-free survival was reduced in cases with FMC7 negativity and/or CD11c negativity.…”

Section: Discussionsupporting

confidence: 77%

Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?

Yıkılmaz

Akıncı²,

Bakanay

et al. 2019

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive disease (Group 2). Group 1 included those who did not require any treatment since diagnosis and those who did not progress after receiving the first step anti CLL treatment. Group 2 included the patients who received C 2 steps treatment. The relation between the two groups was analyzed statistically in terms of clinical, laboratory and flow cytometric findings. Twenty patients (36.3%) required treatment at the time of diagnosis, four patients (3.8%) received first-line treatment during follow-up and 31 (56.3%) patients were followed without any treatment. Thirteen patients required second step treatment after a median of 26.3 months. The risk of progression was found to be increased 5-fold (p = 0.015) in the CD38 positive patient group, 4.2-fold (p = 0.0147) in the FMC7 negative patient group and 2.8-fold in the CD11c negative patient group. FMC 7 negativity decreased total survival 5.9-fold (p = 0.051). Unlike similar publications, we found that patients with CD11c or FMC7 negativity were in a higher need for C 2 step treatment. This suggests that CD11c or FMC7 negativity may be used as a poor prognostic marker in CLL.

show abstract

Section: Discussionsupporting

confidence: 77%